Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of VEC-162 on Circadian Rhythm in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Tasimelteon (Primary)
- Indications Circadian rhythm sleep disorders; Insomnia
- Focus Therapeutic Use
- Sponsors Vanda Pharmaceuticals
- 02 Dec 2008 Results published in The Lancet.
- 10 Nov 2007 Status changed from in progress to completed.
- 10 Jul 2007 New trial record.